Momenta initiated with a Neutral at BTIG. BTIG analyst Thomas Shrader initiated Momenta (MNTA) with a Neutral rating, saying that while he is positive on the company’s IVIg-focused re-positioning, the stock is not cheap and the proof-of-concept for its analytical focus is at least a year away. The analyst also states that the bulk of his modeled value for the company comes from its pipeline development in treating maternal-fetal autoimmune disease, noting that competition in the space is “fierce” and that Momenta is “significantly behind Argenx (ARGX) in the development of FcRn blockers.
https://thefly.com/landingPageNews.php?id=2880297
Monday, March 18, 2019
Health Insurance Innovations upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Randy Binner upgraded Health Insurance Innovations to Buy from Neutral with an unchanged price target of $45. The analyst cites the recent pullback in the shares as well as the company’s growth outlook for the upgrade to Buy. He sees an attractive valuation at current stock levels.
https://thefly.com/landingPageNews.php?id=2880307
https://thefly.com/landingPageNews.php?id=2880307
Novo Nordisk settles U.S. patent litigation on Victoza with Teva
Novo Nordisk (NVO) announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (TEVA) has been reached on the US patent litigation case for Victoza. Consequently, Teva is licensed to launch a generic version of Victoza as of December 22, 2023. Under certain circumstances Teva could launch a generic version of Victoza earlier, but not before 22 March 2023, unless the Victoza(R) patents are no longer in force or there is another generic version of Victoza on the market. If Novo Nordisk is granted six months paediatric extension for Victoza, all above-mentioned timelines will be extended by six months. All other terms of the agreement are confidential. The agreement is subject to review by the US Federal Trade Commission and the US Department of Justice. “This settlement reflects the comprehensive US patent portfolio for liraglutide. Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative drugs against challenges,” said Jesper Brandgaard, executive vice president and head of Biopharm and Legal Affairs of Novo Nordisk.
https://thefly.com/landingPageNews.php?id=2880319
https://thefly.com/landingPageNews.php?id=2880319
Subscribe to:
Posts (Atom)